A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation.
暂无分享,去创建一个
A. Reggiani | M. Mor | G. Tarzia | D. Piomelli | T. Bandiera | A. Armirotti | E. Romeo | M. Maccarrone | G. Moreno-Sanz | F. Bertozzi | V. Capurro | S. Pontis | V. Chiurchiù | Luisa Mengatto | A. Ribeiro | A. Fiasella | A. Nuzzi
[1] D. Piomelli,et al. Advances in the discovery of N-acylethanolamine acid amidase inhibitors. , 2014, Pharmacological research.
[2] M. Mor,et al. 3‐Aminoazetidin‐2‐one Derivatives as N‐Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration , 2014, ChemMedChem.
[3] D. Piomelli,et al. Peripheral gating of pain signals by endogenous lipid mediators , 2014, Nature Neuroscience.
[4] D. Centonze,et al. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis , 2013, Annals of neurology.
[5] B. Cravatt,et al. Chemical Probes of Endocannabinoid Metabolism , 2013, Pharmacological Reviews.
[6] J. O’Shea,et al. Back to the future: oral targeted therapy for RA and other autoimmune diseases , 2013, Nature Reviews Rheumatology.
[7] R. Bertorelli,et al. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models , 2013, PAIN®.
[8] D. Piomelli,et al. Peroxisome Proliferator-Activated Receptor α Mediates Acute Effects of Palmitoylethanolamide on Sensory Neurons , 2012, The Journal of Neuroscience.
[9] Jin Fu,et al. Design and Synthesis of Potent N-Acylethanolamine-hydrolyzing Acid Amidase (NAAA) Inhibitor as Anti-Inflammatory Compounds , 2012, PloS one.
[10] A. Reggiani,et al. β-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine. , 2012, ACS medicinal chemistry letters.
[11] S. Cuzzocrea,et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation , 2009, Proceedings of the National Academy of Sciences.
[12] E. Mazzon,et al. PPAR-α Contributes to the Anti-Inflammatory Activity of 17β-Estradiol , 2009, Journal of Pharmacology and Experimental Therapeutics.
[13] D. Piomelli,et al. Lipidomic analysis of endocannabinoid metabolism in biological samples. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[14] S. Cuzzocrea,et al. Acute Intracerebroventricular Administration of Palmitoylethanolamide, an Endogenous Peroxisome Proliferator-Activated Receptor-α Agonist, Modulates Carrageenan-Induced Paw Edema in Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.
[15] N. Ueda,et al. Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase* , 2005, Journal of Biological Chemistry.
[16] D. Piomelli,et al. The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.
[17] N. Ueda,et al. N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. , 2004, The Biochemical journal.
[18] M. Plotkine,et al. 3-Aminobenzamide reduces brain infarction and neutrophil infiltration after transient focal cerebral ischemia in mice , 2003, Experimental Neurology.
[19] S. Gaetani,et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.
[20] アシュラフ・サエード,et al. Peroxisome proliferator-activated receptor alpha agonist , 2001 .
[21] N. Ueda,et al. Purification and Characterization of an Acid Amidase Selective for N-Palmitoylethanolamine, a Putative Endogenous Anti-inflammatory Substance* , 2001, The Journal of Biological Chemistry.
[22] W. Wahli,et al. The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.
[23] S. Cuzzocrea,et al. Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. , 2015, Pharmacological research.
[24] A. Cavalli,et al. Synthesis and Structure − Activity Relationship (SAR) of 2 ‑ Methyl-4-oxo-3-oxetanylcarbamic Acid Esters, a Class of Potent N ‑ Acylethanolamine Acid Amidase (NAAA) Inhibitors , 2013 .
[25] 김진용,et al. Peroxisome Proliferator-Activated Receptor Alpha , 2003 .
[26] D. Postma,et al. Chronic obstructive pulmonary disease. , 2002, Clinical evidence.
[27] W. Wahli,et al. The PPARalpha-leukotriene B4 pathway to inflammation control. , 1996, Nature.
[28] I. Leodolter. [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.
[29] G PLACITELLI,et al. [Ulcerative colitis]. , 1958, La Riforma medica.